AcquisitionOther
Day One Biopharmaceuticals, Inc. acquired Mersana Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Day One Biopharmaceuticals, Inc. -> Mersana Therapeutics, Inc. · $25 per share plus CVR up to $30.25 per share
To expand into adult oncology and add clinical-stage antibody drug conjugate targeting rare cancer adenoid cystic carcinoma.
Open source record (SEC) ↗